Search clinical trials for: Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A)

Total 11208 results

Parc de Salut Mar
Hospital Infantil Universitario Niño Jesús, Madrid, Spain; Hospital Universitario... and other collaborators

Completed

Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS) (PERSEUS)

Down Syndrome | Fragile X Syndrome

Spain
Parc de Salut Mar

Completed

Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.

Down Syndrome
Parc de Salut Mar

Completed

Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool

Down Syndrome (DS)

Spain
Simons Searchlight
Boston Children's Hospital; Geisinger Clinic; Simons Foundation

Recruiting

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

SMARCA4 Gene Mutation | DDX3X | 16P11.2 Deletion Syndrome | 16p11.2 Duplications | 1Q21.1 Deletion | 1Q21.1 Microduplication Syndrome (Disorder) | ACTL6B | ADNP | AHDC1 | ANK2 | ANKRD11 | ARID1B | ASH1L | BCL11A | CHAMP1 | CHD2 | CHD8 | CSNK2A1 | CTBP1 | CTNNB1 Gene Mutation | CUL3 | DNMT3A | DSCAM | DYRK1A | FOXP1 | GRIN2A | GRIN2B | HIVEP2-Related Intellectual... and other conditions

United States
Chen Xiaoping

Not yet recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC
Immuneering Corporation

Recruiting

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Pancreas Adenocarcinoma | Non-small Cell Lung Cancer | Advanced Solid Tumor (Phase 1) | Malignant Melanoma (Cutaneous)

United States
Sohag University

Recruiting

Assessment of Serum Levels of Janus Kinase 1 and 2 in Patients With Cholinergic Urticaria

Cholinergic Urticaria

Egypt
iVascular S.L.U.

Not yet recruiting

Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy (ANGIODAPT)

Coronary Artery Disease
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) (CASTLE-10)

Hepatocellular Carcinoma

China
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09) (CASTLE-09)

Gastric Cancer Metastatic to Liver

China
Fudan University

Recruiting

Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05) (OPTIONS-05)

Advanced Biliary Tract Cancer

China
Immuneering Corporation

Recruiting

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors

Pancreatic Adenocarcinoma | Advanced Solid Tumor | Non-small Cell Lung Cancer (NSCLC) | Malignant Melanoma (Cutaneous)

United States
Fudan University

Recruiting

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma

China
Enliven Therapeutics

Recruiting

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia

United States, Spain, France, Germany, Korea, Republic of, Australia
Yale University
Boehringer Ingelheim; National Comprehensive Cancer Network

Recruiting

Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck

Squamous Cell Cancers of the Head and Neck

United States
M.D. Anderson Cancer Center

Withdrawn

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

Brain Tumor

United States
RTI International
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Enrolling by invitation

Early Check: Expanded Screening in Newborns

Primary Hyperoxaluria Type 3 | Diabetes Mellitus | Hemophilia A | Hemophilia B | Hereditary Fructose Intolerance | Cystic Fibrosis | Factor VII Deficiency | Phenylketonurias | Sickle Cell Disease | Dravet Syndrome | Duchenne Muscular Dystrophy | Prader-Willi Syndrome | Fragile X Syndrome | Chronic Granulomatous Disease and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Thyroid Gland Medullary Carcinoma | Differentiated Thyroid Gland Carcinoma | Malignant Adrenal Gland Pheochromocytoma | Malignant Paraganglioma

United States
Federico II University
AdvicePharma Group

Active, not recruiting

Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES (PARTHENOPE)

Myocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | Chronic Coronary Syndrome

Italy
Centre Leon Berard

Active, not recruiting

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (VICTORIA)

Endometrial Carcinoma | Hormone Receptor Positive Tumor | Metastatic Carcinoma

France
XRad Therapeutics Inc

Completed

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

Metastasis | Recurrent Cancer | Locally Advanced Solid Tumor

United States
Worldwide Innovative Network Association
Pfizer; ARC Foundation for Cancer Research

Terminated

Survival Prolongation by Rationale Innovative Genomics (SPRING)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB

Israel, United States, Luxembourg, Spain
Sumitomo Pharma America, Inc.

Completed

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Recurrent Ovarian Carcinoma | Colorectal Carcinoma | EGFR Positive Non-small Cell Lung Cancer | BRAF-Mutated Melanoma

United States
Abbott Medical Devices
Bristol-Myers Squibb; Eli Lilly and Company; Daiichi Sankyo, Inc.; Baim Institute...

Completed

XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort (XVU-AV DAPT)

Myocardial Ischemia | Coronary Artery Disease | Coronary Disease | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Vascular Disease | Coronary Artery Stenosis

United States
Advenchen Laboratories, LLC

Active, not recruiting

Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)

Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

Korea, Republic of, Spain, United States, United Kingdom, China, Italy
Seattle Children's Hospital

Active, not recruiting

A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

Lymphoma | Leukemia

United States, Canada
Emma Guttman
Pfizer

Completed

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Cicatricial Alopecia

United States
Hikma Pharmaceuticals LLC

Completed

Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Chronic Myelogenous Leukemia

Jordan, Lebanon, Saudi Arabia, Tunisia
Azevan Pharmaceuticals

Completed

Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder (AVN009)

Intermittent Explosive Disorder

United States
The Christie NHS Foundation Trust
AstraZeneca; Cancer Research UK

Terminated

Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial (DREAMtherapy)

Rectal Cancer

United Kingdom
Novartis Pharmaceuticals
GlaxoSmithKline

Completed

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Neoplasms, Breast

Belgium, United Kingdom, Croatia, Hungary, Argentina, Australia, Germany, Israel, Japan, Poland, Russian Federation, Spain, France, Korea, Republic of, Hong Kong, United States, Brazil, Bulgaria, China, India, Ireland, Italy, Philip... and more
Heidelberg University
Novartis Pharmaceuticals; Siemens Healthcare Diagnostics Inc; Institute of Clinical...

Completed

Unifying Advanced Treatment With Advanced Imaging (GISTm3)

Gastrointestinal Stromal Tumor (GIST)

Germany
Bristol-Myers Squibb

Completed

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

Healthy

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Lymphoma, B-Cell

China
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL)

Non Hodgkin Lymphoma

United States, Australia
Washington University School of Medicine
Tyrogenex

Terminated

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors

Adenocarcinoma | Pancreatic Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Boehringer Ingelheim

Completed

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer (NSCLC)

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Withdrawn

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

Refractory B Acute Lymphoblastic Leukemia | Relapse B Acute Lymphoblastic Leukemia

China
Bristol-Myers Squibb

Completed

A Study to Investigate the Effects of Cytochrome P450 1A2 Induction by Ritonavir on BMS-986165 Drug Levels and Effects in Healthy Participants

Healthy Participants

United States
The Affiliated Hospital of Qingdao University

Unknown

PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC

NSCLC Stage IV | PD-1 | ARID1A

China
Rhizen Pharmaceuticals SA

Completed

Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous | Lymphoma, T-Cell, Peripheral

United States
Institut de Recherches Internationales Servier

Completed

Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

Solid Tumors

Italy, France, Spain
University of Wisconsin, Madison
Tyrogenex

Completed

VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Hutchison Medipharma Limited

Completed

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

NSCLC

China
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Completed

FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Colorectal Cancer

United States
Advenchen Laboratories, LLC

Terminated

Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) (AL3818)

Cervical Cancer | Ovarian Cancer | Endometrial Cancer

United States
Northwestern University
Genentech, Inc.; Amgen; OSI Pharmaceuticals

Completed

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Colorectal Cancer

United States
Pfizer

Terminated

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Endometrial Neoplasms

United States, Canada, Spain, United Kingdom, Japan, Russian Federation, Poland, Australia
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
UMC Utrecht

Unknown

Application of speCtraL Computed tomogrAphy to impRove specIficity of Cardiac compuTed tomographY (CLARITY)

Myocardial Ischemia | Cardiovascular Diseases | Coronary Stenosis

Netherlands

Search clinical trials for: Dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations